Marty St. Clair - Concepedia

Author

Marty St. Clair

Also Known As

Cohen, M.S., Kofron, R., M Clair, M St Clair, M. S. CLAIR, M. S. Clair, M. St Clair, M. St. Clair, M.A. St. Clair, MARTY ST. CLAIR

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

Research Triangle Park Foundation GlaxoSmithKline (United States)GlaxoSmithKline (Canada)Janssen (Belgium)University of North Carolina at Chapel Hill

About

Marty St. Clair is an author at Research Triangle Park Foundation specializing in medicine, hiv, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	1.9K
2	Engineering	6	6	162
3	Public Health	3	3	86
4	Natural Sciences	2	2	95
5	Health Sciences	1	1	22

Marty St. Clair

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink, The Lancet Treatment And PreventionMedicinePhase 2BLong-acting Intramuscular CabotegravirAntiviral Therapy	2017	492
Immunologic Responses Associated with 12 Weeks of Combination Antiretroviral Therapy Consisting of Zidovudine, Lamivudine, and Ritonavir: Results of AIDS Clinical Trials Group Protocol 315 Michael M. Lederman, Elizabeth Connick, Alan Landay, The Journal of Infectious Diseases Immunologic Responses AssociatedImmune ActivationImmunologyAntiviral DrugHuman Immunodeficiency Virus	1998	427
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora, New England Journal of Medicine	2020	427
Relationship between human immunodeficiency virus—associated dementia and viral load in cerebrospinal fluid and brain Justin C. McArthur, Daniel McClernon, Michael F. Cronin, Annals of Neurology	1997	399
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine Raymond F. Schinazi, A. McMillan, Deborah Cannon, Antimicrobial Agents and Chemotherapy Selective InhibitionRacemic FtcMedicinal ChemistryMedicineHuman Immunodeficiency Viruses	1992	290
Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease Hernán Valdez, Elizabeth Connick, Kimberly Y. Smith, AIDS	2002	210
Weather whiplash in agricultural regions drives deterioration of water quality Terrance D. Loecke, Amy J. Burgin, Diego Riveros‐Iregui, Biogeochemistry	2017	193
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis Amy Cutrell, Jonathan Schapiro, Carlo Federico Perno, AIDS	2021	189
Immune Reconstitution in the First Year of Potent Antiretroviral Therapy and Its Relationship to Virologic Response Elizabeth Connick, Michael M. Lederman, Brian L. Kotzin, The Journal of Infectious Diseases	2000	178
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study Chloe Orkin, Shinichi Oka, Patrick Philibert, The Lancet HIV Treatment And PreventionMedicineAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapy	2021	166

Page 1